104 related articles for article (PubMed ID: 3258138)
21. Cytoreductive nephrectomy in metastatic renal cancer.
Flanigan RC
Curr Urol Rep; 2003 Feb; 4(1):36-40. PubMed ID: 12537937
[TBL] [Abstract][Full Text] [Related]
22. The role of adjuvant immunotherapy in renal cell carcinoma.
Mulders PF; De Mulder PH
Curr Urol Rep; 2002 Feb; 3(1):44-9. PubMed ID: 12084219
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors for biologic therapy in kidney cancer.
Drucker BJ
Curr Urol Rep; 2002 Feb; 3(1):31-6. PubMed ID: 12084217
[TBL] [Abstract][Full Text] [Related]
24. Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials.
Atkins MB; Dutcher J; Weiss G; Margolin K; Clark J; Sosman J; Logan T; Aronson F; Mier J;
Med Oncol; 2001; 18(3):197-207. PubMed ID: 11917944
[TBL] [Abstract][Full Text] [Related]
25. The role of resection for patients with renal carcinoma.
Flanigan RC; Yonover PM
Curr Oncol Rep; 2001 Sep; 3(5):424-32. PubMed ID: 11489244
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapeutic approaches for the treatment of breast cancer.
Knutson KL; Schiffman K; Rinn K; Disis ML
J Mammary Gland Biol Neoplasia; 1999 Oct; 4(4):353-65. PubMed ID: 10705919
[TBL] [Abstract][Full Text] [Related]
27. Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes.
Tsurushima H; Liu SQ; Tuboi K; Matsumura A; Yoshii Y; Nose T; Saijo K; Ohno T
Jpn J Cancer Res; 1999 May; 90(5):536-45. PubMed ID: 10391094
[TBL] [Abstract][Full Text] [Related]
28. Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy.
Logan TF; Banner B; Rao U; Ernstoff MS; Wolmark N; Whiteside TL; Miketic L; Kirkwood JM
Clin Exp Immunol; 1998 Dec; 114(3):347-54. PubMed ID: 9844042
[TBL] [Abstract][Full Text] [Related]
29. Multivariate evaluation of prognostic determinants for renal cell carcinomas which are metastatic at initial diagnosis.
Takashi M; Kawai T; Murase T; Wakai K; Ohno Y
Int Urol Nephrol; 1997; 29(3):291-300. PubMed ID: 9285300
[TBL] [Abstract][Full Text] [Related]
30. Effect of recombinant human interleukin 2 on neutrophil adherence to endothelial cells in vitro.
Li J; Gyorffy S; Lee S; Kwok CS
Inflammation; 1996 Aug; 20(4):361-72. PubMed ID: 8872500
[TBL] [Abstract][Full Text] [Related]
31. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.
Luiten RM; Coney LR; Fleuren GJ; Warnaar SO; Litvinov SV
Br J Cancer; 1996 Sep; 74(5):735-44. PubMed ID: 8795576
[TBL] [Abstract][Full Text] [Related]
32. NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice.
Orucevic A; Lala PK
Br J Cancer; 1996 Jan; 73(2):189-96. PubMed ID: 8546905
[TBL] [Abstract][Full Text] [Related]
33. The possible use of spleen cells for the adoptive immunotherapy of cancer patients.
Katano M; Yamamoto H; Kubota E; Nakamura M; Matsuo T; Nagumo F; Hisatsugu T; Katsuki T; Tadano J
Surg Today; 1993; 23(1):13-20. PubMed ID: 8461601
[TBL] [Abstract][Full Text] [Related]
34. Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy.
Schomburg A; Kirchner H; Atzpodien J
J Cancer Res Clin Oncol; 1993; 119(12):745-55. PubMed ID: 8408187
[TBL] [Abstract][Full Text] [Related]
35. Adoptive immunotherapy with peripheral blood lymphocytes cocultured in vitro with autologous tumor cells and interleukin-2.
Sporn JR; Ergin MT; Robbins GR; Cable RG; Silver H; Mukherji B
Cancer Immunol Immunother; 1993 Aug; 37(3):175-80. PubMed ID: 8392912
[TBL] [Abstract][Full Text] [Related]
36. Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha.
Landmann R; Keilholz U; Scheibenbogen C; Brockhaus M; Gallati H; Denz H; Bargetzi M; Ludwig C
Cancer Immunol Immunother; 1994 Feb; 38(2):113-8. PubMed ID: 8306366
[TBL] [Abstract][Full Text] [Related]
37. In vivo cytokine production and recombinant interleukin 2 immunotherapy: an insight into the possible mechanisms underlying clinical responses.
Deehan DJ; Heys SD; Simpson WG; Broom J; Franks C; Eremin O
Br J Cancer; 1994 Jun; 69(6):1130-5. PubMed ID: 8198981
[TBL] [Abstract][Full Text] [Related]
38. Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.
Ravaud A; Négrier S; Cany L; Merrouche Y; Le Guillou M; Blay JY; Clavel M; Gaston R; Oskam R; Philip T
Br J Cancer; 1994 Jun; 69(6):1111-4. PubMed ID: 8198979
[TBL] [Abstract][Full Text] [Related]
39. Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs.
Helfand SC; Soergel SA; MacWilliams PS; Hank JA; Sondel PM
Cancer Immunol Immunother; 1994 Aug; 39(2):84-92. PubMed ID: 8044833
[TBL] [Abstract][Full Text] [Related]
40. Long-term serum/plasma-free culture of human cytotoxic T lymphocytes induced from peripheral blood mononuclear cells.
Liu SQ; Shiba R; Kim BS; Saijo K; Ohno T
Cancer Immunol Immunother; 1994 Nov; 39(5):279-85. PubMed ID: 7987858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
